Plain-English translation of NCT07437898 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy medication called given together with to people with locally advanced esophageal squamous cell carcinoma (a specific type of esophageal cancer). The treatment is given before surgery to try to shrink the cancer and make it easier to remove completely. Researchers want to see how well this medication works and whether it's safe for patients.
Esophageal cancer is serious, and patients with advanced disease have limited treatment options. This medication works differently than traditional by helping the body's immune system fight cancer cells. The trial exists to see if combining this new approach with standard can improve outcomes for patients who are candidates for surgery.
You likely qualify if…
You likely don't qualify if…
You would receive combined with (paclitaxel and cisplatin) in cycles over several weeks at the hospital or clinic. After completing this treatment, you would have imaging scans to check how well the medication worked, and then you would proceed to surgery to remove the cancer. Throughout the trial, you'll have regular blood tests and clinic visits to monitor your health and any side effects.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China